Phase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis

Trial Profile

Phase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs POL 6014 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Santhera Pharmaceuticals
  • Most Recent Events

    • 19 Jun 2018 Status changed from planning to recruiting.
    • 15 Feb 2018 According to a Santhera Pharmaceuticals media release, this trial is planned to initiate in the second half of 2018.
    • 12 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top